Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Suspended 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Classical hematology 1

Conditions

Myelodysplastic Syndromes 1Leukemia, Myeloid, Acute 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Whole-Body Irradiation 5fludarabine phosphate 4Cyclophosphamide 4Peripheral Blood Stem Cell Transplantation 3Mycophenolic Acid 3Cyclosporine 3Busulfan 3Tacrolimus 2Methotrexate 2Melphalan 2Etoposide 2Azacitidine 2venetoclax 1merphos 1ivosidenib 1fludarabine 1Vorinostat 1Thiotepa 1TAK-243 1Specimen Handling 1Sirolimus 1Rituximab 1Lenalidomide 1Cord Blood Stem Cell Transplantation 1Clofarabine 1CT-P10 1Biopsy 1Antilymphocyte Serum 111-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Anemia, Refractory, with Excess of Blasts × TAK-243 × 30 days × Clear all
NCT03816319 2026-05-18

TAK-243 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes With Increased Blasts

National Cancer Institute (NCI)

Phase 1 Suspended
42 enrolled
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡